Sutro Biopharma (FRA:S090) Interest Expense: €-36.02 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:S090 Sutro Biopharma Inc FRA:S090
41 GF Score
Price €21.20
GF Value €9.71
! 4 Warning Signs
View Full Analysis

What is Sutro Biopharma Interest Expense?

Sutro Biopharma FRA:S090 -5.36% 41 Interest Expense is €-36.02 Mil as of Mar. 2026. GuruFocus rates FRA:S090 with a GF Score™ of 41/100 and a GF Value™ of €9.71. The stock has 4 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sutro Biopharma's interest expense for the three months ended in Mar. 2026 was € -9.06 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-36.02 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sutro Biopharma's Operating Income for the three months ended in Mar. 2026 was € -25.62 Mil. Sutro Biopharma's Interest Expense for the three months ended in Mar. 2026 was € -9.06 Mil. Sutro Biopharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sutro Biopharma  (FRA:S090) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sutro Biopharma's Interest Expense for the three months ended in Mar. 2026 was €-9.06 Mil. Its Operating Income for the three months ended in Mar. 2026 was €-25.62 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €5.22 Mil.

Sutro Biopharma's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Sutro Biopharma did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Sutro Biopharma Interest Expense Historical Data

* Premium members only.

The historical data trend for Sutro Biopharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sutro Biopharma Interest Expense Chart

Sutro Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.78 -3.16 -21.78 -29.67 -35.92

Sutro Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.84 -9.27 -8.87 -8.82 -9.06
FRA:S090
41GF Score
Sutro Biopharma Inc FRA:S090
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sutro Biopharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-36.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-36.02 Mil mean?
Sutro Biopharma (FRA:S090) has a Interest Expense of €-36.02 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Sutro Biopharma and its competitors.
Is Sutro Biopharma's Interest Expense too high?
Sutro Biopharma's current Interest Expense is €-36.02 Mil. Overall, Sutro Biopharma has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Sutro Biopharma's Interest Expense compare to NGNE and OCGN?
Sutro Biopharma's Interest Expense of €-36.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Sutro Biopharma and its competitors. Sutro Biopharma's current Interest Expense is €-36.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sutro Biopharma stock overvalued right now?
Sutro Biopharma (FRA:S090) has a current Interest Expense of €-36.02 Mil. The stock's GF Value™ is €9.71, compared to a current price of €21.20 — trading 118.3% above its estimated fair value. The current Interest Expense is €-36.02 Mil. Sutro Biopharma's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Sutro Biopharma (FRA:S090), the current Interest Expense is €-36.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sutro Biopharma (FRA:S090) Overvalued in 2026?

Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued. The current stock price of €21.20 is trading 118.3% above its estimated GF Value™ of €9.71.

Key valuation signals for FRA:S090:

  • Interest Expense: €-36.02 Mil
  • GF Value™: €9.71 vs. price of €21.20 (118.3% above fair value)
  • GF Score™: 41/100 with 4 warning signs

No single metric tells the full story. See the FRA:S090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sutro Biopharma Business Description

Other Exchanges STRO:USA
Address 111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
41GF Score

Get the complete analysis for FRA:S090

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.20
Price
€9.71
GF Value